The nationwide opioid litigation movement reached its first major settlement
The public still won't hear details regarding Purdue Pharma's push to market the painkiller OxyContin. Testimony from members the company's founding family, the Sacklers, won't happen either.
The pharmaceutical giant reached a $270 million dollar settlement on Tuesday with the state of Oklahoma, and legal experts argue that the settlement could help set a floor amount for other lawsuits filed against Purdue and the Sacklers, The Wall Street Journal reports. Oklahoma's attorney general claimed that Purdue's aggressive marketing tactics for OxyContin and other prescription painkillers helped fuel America's opioid crisis; the two sides reached the agreement just two months before the scheduled trial.
The New York Times reports that $100 million from the settlement will fund an addiction treatment and research center at Oklahoma State University in Tulsa, $70 million will pay Oklahoma cities, counties, and Native American tribes and to reimburse the state for its litigation costs. The Sacklers, who were reportedly not named in the lawsuit, will contribute an additional $75 million over five years.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Other companies involved in the lawsuit, such as Johnson and Johnson, have not settled, however. The trial, therefore, is still scheduled for May 28.
Purdue and the Sacklers, meanwhile, still face more than 1,600 opioid lawsuits from 37 states, and numerous cities, counties, and tribes across the United States. For the time being, though, the public won't hear "full recounting of Purdue's actions in promoting OxyContin to doctors and underplaying its addictive properties," writes the Times.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
'A direct, protracted war with Israel is not something Iran is equipped to fight'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Today's political cartoons - April 17, 2024
Cartoons Wednesday's cartoons - political anxiety, jury sorting hat, and more
By The Week US Published
-
Arid Gulf states hit with year's worth of rain
Speed Read The historic flooding in Dubai is tied to climate change
By Peter Weber, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Tianeptine: why lawmakers fear a new kind of opioid
The explainer The drug is sold over the counter. And is highly addictive.
By Devika Rao, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
How polysubstance abuse is worsening the American opioid crisis
The Explainer Studies are showing that more Americans are struggling with dependency on multiple substances.
By Theara Coleman, The Week US Published